Unique enteral feeding to reduce reflux & Ventilator Associated Pneumonia (VAP)
OVERVIEW
LunGuard developed a novel solution for the future of critical care medicine (ICU). The new approach of the “Personalized Physiological Medicine (PPM)” based on a peristaltic enteral feeding tube that is structured from several inflatable balloons used as a multi-sensory platform. LunGuard’s innovative solution, together with the substantial clinical need, is designed to safely block Gastro Esophageal Reflux (GER) & reduce the cause Ventilator Associated Pneumonia (VAP). VAP leads to clinical complications requiring complex medical treatment, deteriorated patient conditions & prolonging the patient’s length of stay (LOS). LunGuard recently successfully accomplished a clinical trial with 20 patients & with significant clinical outcomes. A medical paper has been published. An additional study with 30 patients is expected for CE approval.
Saves money and resources
-
Lower Length Of Stay
-
Saves money invested in treating nosocomial complications
-
Less staff resources
LunGuard Clinical Studies shows
-
80% of control group gets Micro Aspiration of Gastric Fluids
-
USING LunGuard only 20% incidents of Micro Aspiration of Gastric Fluids
Keep gastric fluids in the stomach
-
Reduces the incidence of reflux regurgitation
-
Actively pumping oral/nasal and gastric secretions into the stomach
-
Reduces reflux clinical consequences
-
Significantly Reduces VAP
PROBLEM
The problem - Nosocomial Infections in ICU
-
Pneumonia constitutes highest percentage of nosocomial infections in ICUs
Resulting in cost increase and financial loss for the hospitals
- Length Of Stay (LOS) and treatment of medical complications
-
Ventilated Associated Pneumonia (VAP) is a major complication
- approx. 25% of all invasive ventilated patients in China get VAP
- approx. 30% in the USA and 40% in Germany suffer from VAP
-
Current applicable prevention measures for VAP are considered to be insufficient
Critical Care – unmet need
Current standard of care
-
Patients are usually Ventilated, Sedated, on antacids and fed through a NasoGastric tube
Possible clinical consequences
-
Peristaltic action of the oesophagus is impaired, open GE sphincter, sub-optimal ventilation, Increased bacterial risk of infection, Sub-optimal feeding
Patient’s infections
-
Gastric fluids with bacteria travel into the patient’s airway and reach the lungs causing infections
-
90% of enteral fed patients aspirate gastric contents
-
Aspiration of gastric contents is a major risk factor of pneumonia, resulting in complications and mortality
Unmet need
-
Reduce the clinical consequences of the peristaltic action of the esophagus (reflux) to diminish patient infection and AVP (Associated Ventilation Pneumonia)
-
Cost savings of $1,200 - $17,000, per ventilated patient, for full prevention of VAP
SOLUTION
Enteral feeding Gastric Fluids Prevention Technology
LunGuard – The Product
-
Position to become the “standard-of-care” in enteral-fed ventilated patients
-
It enhance and optimise the efficiency and safety for both ventilation and feeding
-
Reduces aspiration of gastric fluids compared to regular NG tube
-
Strong IP portfolio
LunGuard’s Nutrition Advantage
-
KEEP GASTRIC FLUIDS IN THE STOMACH
-
PROTECT THE TRACHEA AND LUNGS FROM CONTAMINATION
-
PFT mimics the Peristaltic esophagus movement
-
Reducing reflux clinical consequences
-
Acts as a one-way valve allowing saliva secretion
-
Improve trade-off between under-feeding patients and lowering aspiration risk
-
Better nourished patients have better treatment outcomes at a lower cost
-
allowing feeding throughout the 24h without a night-time break due to aspiration risk
-
Increases nutrition up to 25% by allowing earlier and more efficient feeding rate in a moderated reflux environment
MARKET
Global Enteral Feeding Market
Accounts for:
-
$1.8b in 2015
-
$ 2.3b by 2021 (forecasted)
Market Share
-
China - $80m
-
Germany - $170m
-
USA - $800m
Compound Annual Growth Rate (CAGR)
-
China - 30%
-
USA - 3%
-
Germany - 1.7%
Potential Market and Value - Reduced Reflux & VAP
POTENTIAL MARKET SAVINGS USING LunGuard
$3.1b
Intensive Care Units (ICUs)
each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the chosen modalities. Medvest has a long term
Intensive Care Units (ICUs)
each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the
$850m
Intensive Care Units (ICUs)
each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the chosen modalities. Medvest has a long term
Intensive Care Units (ICUs)
each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the
300%
Intensive Care Units (ICUs)
each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the chosen modalities. Medvest has a long term
Intensive Care Units (ICUs)
each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the
TEAM
MANAGEMENT
Ofer Pintel - CEO & Co Founder (BSc. MSc. MBA)
Experienced entrepreneur in the medical device industry.
Professional graduation from the Technion M.Ac, B.Sc and MBA
David Akunis, Chairman of the Board; Managing Partner at MEDVEST UK LLP, (Investment Banker and V.C.)
• MP at Medvest, focus on Israel
• Previously VP & investment manager at prestigious international VC and PE firms
• Former head of the Medical and biotech equipment department at the Israeli Ministry of Export
R&D team (under Dagesh F.K)
.
BOARD OF DIRECTORS
Barbara Faktor, Board member (Israel)
• CEO of Rishonim medical center, Rishon Letzion
• Director at NIMedical
Kobi Franken - Dagesh F.K
.
SCIENTIFIC ADVISORY BOARD
Prof. Pierre Singer, Chairman (Israel)
• Director of General Intensive care unit, Hadassah medical
Prof. Vernon van Heerden,Scientific advisor (Israel)
• Senior ICU physician, Hadassah University Hospital, Israel, MD
Prof. Stephen A. McClave, Scientific advisor (USA)
• Director of Clinical Nutrition at the University of Louisville School of Medicine
Dr. Yaron Avitzur, Scientific advisor (Canada)
• Medical Director, Intestinal rehabilitation and transplantation, Hospital for Sick Children, Toronto